RECRUITING

Thromboxane Function in Women With Endometriosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to compare neurovascular regulation in women with endometriosis and healthy women. The main questions it aims to answer are: * Do women with endometriosis have greater blood pressure and pain responses to a stimulus than healthy women? * Do women with endometriosis have greater platelet activity than healthy women? Participants will take aspirin and/or placebo and will: * perform hand grip exercise and cold pressor tests * undergo iontophoresis and blood draw Researchers will compare women with and without endometriosis to see if there is a difference in neurovascular regulation.

Official Title

The Role of Thomboxane A2 and it's Receptor in Vascular Regulation in Women With Endometriosis

Quick Facts

Study Start:2024-01-01
Study Completion:2027-08-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05962034

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Born with a uterus
  2. * 18-45 years old
  3. * With and without endometriosis
  1. * Currently pregnant or breastfeeding
  2. * Diagnosed cardiovascular disease
  3. * BMI over 35
  4. * Nicotine use (e.g., smoking, chewing tobacco, vaping, etc.)
  5. * Currently using hormone replacement therapy (or have used within previous 6 months)
  6. * Known skin allergies or current rash, skin disease, disorders of pigmentation
  7. * Diabetes
  8. * Renal disease, renal artery stenosis, renal impairment
  9. * Liver disease
  10. * Stage II Hypertension (blood pressure \>140/\>90 mmHg)
  11. * Hypotension (blood pressure \< 90/60 mmHg)
  12. * Raynaud's syndrome
  13. * Any current medications which could conceivably alter cardiovascular responses (e.g. antihypertension medication, diuretic, digoxin)
  14. * Allergy or hypersensitivity to investigational agents
  15. * Immunosuppressed/immunocompromised

Contacts and Locations

Study Contact

Lacy Alexander, Ph.D.
CONTACT
8148671781
lma191@psu.edu
Sue Slimak, RN
CONTACT
8148638556
sks31@psu.edu

Study Locations (Sites)

Noll Laboratory
University Park, Pennsylvania, 16802
United States

Collaborators and Investigators

Sponsor: Penn State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-01
Study Completion Date2027-08-01

Study Record Updates

Study Start Date2024-01-01
Study Completion Date2027-08-01

Terms related to this study

Keywords Provided by Researchers

  • Endometriosis
  • Aspirin

Additional Relevant MeSH Terms

  • Endometriosis